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Abstract
Although Costa Rica has no explicit constitutional right to health, its constitutional cham-
ber of the Supreme Court (Sala IV) has become increasingly central to the resolution of 
many health care decisions. Some argue that courts’ decisions about individuals’ access to 
very expensive medications could upset the country’s medical priorities and harm the state’s 
general health care provision capacity. This article assesses whether health rights litigation 
concerning the right to medications leads to more fairness in access to medications in Costa 
Rica. We review randomly selected access to medicines cases successfully claimed at the 
Sala IV in 2008 and classify them into four priority groups using standard priority-setting 
criteria. We find that 2.7% of the successful cases fall into priority group I (highest priority), 
27% in group II, 48.6% in group III, and 21.6% in group IV (experimental treatment). Our 
analysis reveals a majority of successful health rights litigation for medications results in 
court-mandated provision of new, expensive drugs, many with only marginal benefits. More 
than 70% of the successful cases evaluated concerned medications judged to be of low prior-
ity. Based on these cases, we cannot conclude that litigation leads to more fairness in access 
to medications.
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In  recent years, court cases litigating a right to 
health have grown rapidly in many countries, which 
has sparked a major debate concerning whether this 
litigation leads to more fairness in access to med-
icines and distribution of health benefits. While a 
major study led by Varun Gauri and Daniel Brinks 
draws relatively positive, if nuanced, conclusions 
concerning the impact of litigation on social rights, 
including health rights, a subsequent multi-country 
study led by Alicia Yamin and Siri Gloppen that fo-
cuses exclusively on health rights litigation is more 
agnostic in its conclusions and finds “that health 
rights litigation is neither a dangerously infectious 
trend to be urgently contained nor a panacea for 
health inequity.”1 Here, we investigate the effects 
of litigation on priority setting and social justice 
through a case study of Costa Rica, which has expe-
rienced an explosion in health rights litigation since 
the late-1990s. The many court cases gave rise to a 
vocal debate between the leaders of the health care 
system and constitutional magistrates. The debate 
has been played out in court decisions and scholarly 
publications as well as in the national media. To 
assess the health impacts of the court decisions, we 
need to know who benefits from them, in terms of 
patient groups, as well as the distribution of bene-
fits: how much are these persons helped, compared 
to other patients in need?2 A starting point is to look 
at the forms of treatment that are successfully liti-
gated, and then use medical evidence regarding the 
individual burden of disease and the effectiveness of 
treatment for the condition in question to assess the 
distributional consequences of the court decisions.
 We know that some of the earliest successful 
health rights litigation cases, in Costa Rica and 
many other countries in the early 1990s, concerned 
people living with HIV/AIDS.3 Since then, there 
have been many other medical cases litigated rang-
ing from essential medicines to high-cost cancer 
treatments, multiple sclerosis, and kidney failure, as 
well as cases concerning waiting times for surgeries 
and in vitro fertilization (IVF). What we don’t know 
is whether according these successfully litigated 
treatments higher priority makes the health system 
fairer. The answer, in part, depends on the prior 
situation of different patient groups: do other pa-
tients have unmet needs for which they could have 
been helped more with the same resources? These 
questions are examined through an in-depth study 
of the nature and impact of successful litigation for 
medications in Costa Rica.
Costa Rica
Costa Rica is a small Central American country 
with a population of 4.8 million and is one of the 
oldest, most democratic countries in the Americas.4 
Costa Ricans enjoy an extensive, government-pro-
vided social welfare system covering insurance, 
health care, pensions, and education, among other 
services.5 The success of this generous welfare sys-
tem and virtually universal health care system is 
reflected in the country’s relatively high Human De-
velopment Index (HDI) rank of 54th in the world.6 
Despite a GNI per capita (PPP) of US$10,863 and 
per capita government expenditure on health at 
(PPP) is $932 (in 2012), key health indicators are 
very good, especially in comparison with the coun-
try’s Central American neighbors.7 For example, life 
expectancy at birth is 78.7 years (77.4 years for males 
and 81.3 for females), and the under-five mortality 
rate is 10 per 1,000 live births; these are among the 
best rates in the Americas.8
Courts and health rights
Historically, Costa Rica’s Supreme Court was, like 
most Latin American Supreme Courts, a moribund 
institution that was unable and unwilling to pro-
tect people’s individual or collective constitutional 
rights. A 1989 constitutional reform created a Con-
stitutional Chamber of the Supreme Court (Sala 
Constitucional or Sala IV) with far-reaching judi-
cial review powers: the Sala IV has become one of 
the most assertive and politically significant courts 
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in the Americas. Apart from exercising an emphatic 
accountability function, the court has been willing 
and able to support and enforce an expansive range 
of individual rights.9 The court effectively opened 
a significant new legal opportunity structure that 
political parties, individuals, and groups from vir-
tually every sector of society have used. These range 
from the weakest, most marginalized individuals, 
including prisoners and people living with HIV/
AIDS, to the most powerful, including multination-
al businesses and former presidents.10 The superior 
court abandoned its previous legal formalism and 
instead allows any individual to file a case directly 
with the Sala IV with no charge and no need to hire 
legal representation. The court is open 365 days a 
year, 24 hours a day. Thus, the court leveled the 
judicial playing field for all claimants and has had 
a profound impact on the balance of political pow-
er in the country. It has brought the constitution 
to life, placing it at the center of all political and 
rights questions in the country. According to one 
Sala IV magistrate, Eduardo Sancho, the role of the 
constitutional court from its inception has been to 
“protect the rights of people.”11
The right to health in Costa Rica
Figure 1 shows a rapid increase in litigation fol-
lowing the inauguration of the Sala IV, but it was 
not until the early 1990s that the first health rights 
cases were filed. This is in part because Costa Rica’s 
current (1949) Constitution contains no explicit, 
fundamental right to health. Rather, the Consti-
tutional Chamber of the Supreme Court after its 
creation in 1989 constructed a constitutional right 
to health. According to the court, this right to 
health is derived from the Constitution’s protection 
of human life (Article 21), the right to social secu-
rity protection (Article 73), and many international 
Human Rights conventions to which Costa Rica 
is a signatory.12 These international human rights 
treaties are treated by the Sala IV as having an “al-
most supra constitutional value,” which has helped 
facilitate a gradual expansion of a justiciable right 
to health that the court has been willing and able to 
respond to positively and quickly.13
 One of the earliest health rights cases the Sala 
IV examined, in 1992, involved a person living 
with HIV/AIDS who filed a claim with the court 
to demand that the state-funded health care system 
(the Costa Rican Social Security Fund, Caja Costar-
ricense de Seguro Social, CCSS) provide and pay 
for the anti-retroviral (ARV) medication azidothy-
midine. The CCSS had denied the patient’s access 
to the medication. In response to the litigation, the 
CCSS argued that the drugs were not on the coun-
try’s list of essential medicines because they were too 
expensive and were not a cure for HIV/AIDS. The 
Sala IV accepted the CCSS’s argument, noting that 
an individual’s right to health were necessarily lim-
ited by scarce financial resources, and ruled against 
the claimant, denying him state-funded access to 
the medication.14 The Court’s restricted notion of a 
right to health was maintained over the following 
five years, during which time only 25 more medica-
tion cases were filed with the Sala IV; these resulted 
in only nine successful claims. Of those nine, seven 
were merely patients requesting permission to take 
their current medications at home instead of at a 
medical facility.15
 The Sala IV’s health rights jurisprudence began 
to change in 1997, when three HIV/AIDS patients 
filed a similar case to the failed 1992 ARV case. In 
1997, highly effective triple combination ARV ther-
apy had been developed and was in use in the US 
and other countries. In response to the new litiga-
tion, however, the CCSS made the same cost-based 
argument it had successfully employed in the 1992 
case. This time, though, the Sala IV’s health rights 
jurisprudence had developed to the point where 
the right to health was considered to be a justicia-
ble constitutional right. The Sala IV’s 1997 decision 
reversed its 1992 ruling, deciding in favor of the 
plaintiffs and ordering the CCSS to supply and pay 
for the necessary medications. The court argued, 
“What good are the rest of the rights and guarantees 
. . . [or] the advantages and benefits of our system 
of liberties, if a person cannot count on the right to 
life and health assured?”16 The justification for the 
court’s ruling in this case became the foundation 
stone of all health rights jurisprudence and has 
been expanded and clarified in subsequent rulings. 
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In 2003, for example, the Sala IV deliberated for just 
one hour before ruling against the CCSS’s medical 
experts and forcing it to pay for Cerezyme, at an an-
nual cost of $175,000, for a young girl with Gaucher 
disease.17 The court’s jurisprudence relating to the 
provision of high-cost medications is clearly stated 
in a 2007 decision when the court argued that the 
CCSS cannot decline to fill prescriptions prescribed 
by a patient’s treating physician for “eminently 
economic reasons.”18 Instead, the court argued, 
the CCSS is “under the undeniable obligation” to 
supply them, even if they are not on the CCSS’s 
official list. This increasingly expansive definition 
of the right to health has been frequently cited in 
many subsequent cases and, as seen in Figure 1, lit 
a slow-burning jurisprudential fuse that eventually 
resulted in an explosion of health rights cases.19
 Although the ruling was originally inter partes 
(applying only to the people involved in this par-
ticular case), the subsequent deluge of cases filed by 
HIV/AIDS patients were decided by the Sala IV in 
the same manner and with the same reasoning, ef-
fectively making it erga omnes (a court decision that 
applies to all similar situations). Consequently, the 
CCSS provides ARV medications to all patients with 
a valid prescription from a CCSS doctor, resulting 
in the highest coverage of HIV/AIDS patients in 
Latin America. The impact of this decision was re-
markable and fast; morbidity rates for people living 
with HIV and AIDS declined significantly after the 
1997 decision, reversing the trend of the 1980s and 
1990s.20
 The lessons of the Sala IV’s HIV/AIDS medi-
cation decision were recognized not just by other 
people living with HIV/AIDS, but by patients suffer-
ing from other chronic illnesses who subsequently 
used the legal opportunity provided by the Sala IV 
to claim and win access to expensive medications, 
even if the CCSS had previously denied their 
claims.21 According to Carlos Zamora—a medical 
doctor who works in the actuarial division of the 
CCSS—the 1997 decision was “perhaps the most 
relevant case in the rights to medication arena…the 
arguments put forth and the Sala IV’s interpretation 
has served as a model that has shaped the field of 
health rights.”22
 Since the success of the 1997 decision, the num-
ber of amparo (a writ to protect or reestablish 
constitutional rights or human rights contained in 
international instruments to which Costa Rica is 
a signatory) cases claiming a right to medications 
increased gradually with some fluctuations before 
it exploded from 2002 onwards. While this rapid-
ly increasing quantity of cases might discourage 
claimants from filing claims, the court has made 
great effort to reduce the length of time it takes to 
reach a decision on amparo cases. In the court’s 
early years of operation, the average time to resolve 
an amparo case was 12 weeks, then, as a result of the 
rapid growth in caseload, it increased to five months 
by 2003. From 2003 onward, that time fell, reaching 
an average of seven weeks in 2011.23 While the vast 
majority of health rights claims are amparo cases, 
the court treats these cases as a special category and 
requires letrados (clerks to the court) to give them 
priority above all other cases except habeas corpus 
cases, dedicating one day per week to resolving 
health cases as quickly as possible. Also, while the 
vast majority of amparo cases are unsuccessful 
(approximately 75 percent), medical amparo cases 
tend to succeed more often. In the period under 
discussion here, medical amparo claims against the 
CCSS succeeded in over 60 percent of the cases.24 
In most cases, the court has argued that “the spe-
cialist doctor who treats a patient knows better than 
anyone else their reality and needs” and that a pre-
scription from that doctor outweighs the technical 
medical criteria used by the CCSS’s Comité Central 
de Farmacoterapia (Central Committee of Pharma-
cotherapy) to determine which medicines should 
be on the essential drugs list.25
 While it is clear that the number of cases has been 
increasing since 1997, little is known about the scope, 
outcome, and impact of those cases. Hogerzeil et al. 
report that in 2006, seven cases related to essential 
medicines won in Costa Rica. Their impact on the 
health system and its allocation of scarce health care 
resources is not known. As noted by Hogerzeil et al.:
most public budgets are not infinite and at a certain 
moment choices have to be made. Progressive im-
plementation of the right to health requires a State 
to choose which components should be implement-
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ed first. Under such circumstances, should courts 
of justice or national committees of experts decide 
how public funds are spent in the most equitable 
and cost-effective manner?26
 Although several types of health-related cases are 
brought to the constitutional court, such as cases 
related to non-discrimination, surgeries, waitlists, 
quality of care, and others, a particularly interesting 
class of cases concerns access to medications. These 
cases are also the source of much of the criticism 
against the Sala IV from members of the CCSS who 
argue that these health rights medication decisions 
lead to the misallocation of scarce resources, cor-
ruption by unscrupulous lawyers and doctors acting 
on behalf of pharmacy companies, and by foreign-
ers accessing court-mandated free medicines. Does 
the court secure individuals’ access to high-priority 
medicines that the publicly funded health care sys-
tem in Costa Rica should have provided or, arguably, 
should have put them on the essential drugs list? Or 
does the court decide with claims that from a public 
health or social justice perspective would be seen as 
a low priority? In short: does health rights litigation 
concerning the right to medications lead to more 
fairness in access to treatment and distribution of 
health benefits?
 In this paper, we review 37 successful cases from 
Costa Rica concerning access to medicines brought 
to the Sala IV in 2008. We classify them according 
to standard fairness criteria from the public health 
and priority-setting literature.
Material and methods
The bars in Figure 1 show the rapid increase in the 
total number of cases filed with the Sala IV since its 
inception in 1989; the solid line reflects the number 
of amparo cases filed, which have historically ac-
counted for almost 80% of the total caseload. Figure 
2 illustrates the growth in the total number of cases 
based on the right to health. Figure 3 shows the de-
velopment of a litigation strategy used by patients 
to file cases at the Sala IV against the CCSS to make 
a claim for a specific medication. The solid line in 
Figure 3 shows the increasing number of successful 
cases claiming a right to medications that the CCSS
Figure 1  Sala IV total caseload and amparo cases, 
1989-2013 
Source: Sala IV, 2014
Figure 2  Health rights claims filed against CCSS, 
1989-2008
Source: Zamora Zamora, 2010
Figure 3  Medication claims filed against CCSS, 
1989-2011
Source: Zamora Zamora, Amparos contra la Caja Costar-
ricense de Seguro Social, 2009 to 2011. Preliminary report, 
February 2014
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had previously denied. Taken together, these figures 
clearly demonstrate a delayed learning effect where 
claimants appear to have slowly recognized the 
creation of an effective legal opportunity that would 
allow them to approach the court to obtain medica-
tions that the CCSS had previously denied. 
 To investigate the impact of this health rights 
litigation, we created a database of all the right to 
health cases filed with the Sala IV against the CCSS 
in Costa Rica for the year 2008. This database al-
lows us to look deeper into these cases and conduct 
an evaluation of their impact on the equitability 
of the health system. In total, there were almost 
18,000 cases filed, the vast majority (16,345) writs 
of amparo, of which approximately 500 were right 
to health cases.27 Of those cases, 192 were claims 
for medications, with approximately 50% of those 
cases winning their litigation. We then randomly 
selected 37 successful cases and extracted a brief 
description of the case, the medication involved, 
and the judicial basis of the court’s decision. Sec-
ond, we searched for published cost-effectiveness 
studies and reports where these medicines have 
been evaluated according to the methods of health 
technology assessment (HTA).28 We used PubMed 
to identify published academic studies, and the 
website of the National Institute for Health and 
Clinical Excellence (NICE) in the UK as a starting 
point for relevant and up-to-date publicly available 
HTA reports. Third, we extracted priority-relevant 
medical evidence concerning health outcomes and 
costs from the identified studies and reports. “Pri-
ority-relevant evidence” was defined as information 
necessary to evaluate the effectiveness of a given 
medication, its overall costs, and the severity of 
condition for a typical patient in need of medica-
tion. In addition, we extracted information about 
the quality of evidence concerning health outcomes 
and costs. After extracting priority-relevant evi-
dence for the medications in question, we explicitly 
evaluated each medicine according to predefined 
criteria for priority classification. Finally, we sum-
marized all evidence for each criterion, combined it 
into an overall assessment, and classified each med-
icine into one of four priority groups with declining 
rank of importance from a standard public health 
priority-setting perspective.
Analytical framework
Most scholars agree that the two main goals for 
health systems are: efficiency and fairness in the 
distribution of health and health care.29 While peo-
ple disagree on the relative weight accorded to the 
different concerns, almost all theories of resource 
allocation in health care would recognize the 
following as criteria for assessing the priority of a 
given condition and its intervention:30
1. The severity of disease without the new med-
icine
2. The effectiveness of the new medicine
3. The cost-effectiveness of the new medicine
4. The quality of evidence on 1-3
In concrete cases, this information can be formu-
lated in terms of the patient’s characteristics, the 
nature of the condition, and the health intervention 
in question. We developed a framework for prior-
ity classification based on such standard fairness 
criteria from the public health and priority-setting 
literature:
Priority group I = High priority
Priority group II = Medium priority
Priority group III = Low priority
Priority group IV =  Experimental interventions
By experimental interventions, we mean interven-
tions judged as experimental according to evidence 
by a trustworthy health technology assessment 
agency. An intervention for a given condition is 
assigned high priority if it addresses a severe con-
dition (where the prognosis is poor in terms of lost 
life years or reduced quality of life), if it is highly 
effective (improves the prognosis with regard to 
life years or quality of life), and if it is reasonably 
cost-effective. The measure of effectiveness used in 
most HTA reports and cost-effectiveness studies 
is the quality-adjusted life year (QALY). We grade 
clinical effectiveness in terms of QALYs. We use a 
threshold of > 1 QALY for very effective (grade I). 
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For studies where severity of disease was not report-
ed, we extracted relevant information and indirectly 
estimated the health gap by using QALY gain with 
standard treatment with the help of life tables for 
the relevant country. For example, if a 40-year-old 
patient from Costa Rica with terminal breast cancer 
had a prognosis of 1 QALY, her health gap was cal-
culated as life expectancy at age 40 (= 42.2) minus 
1 QALY (= 41.2). We use this as an indicator of her 
severity of disease. We classified a condition as very 
severe (grade I) if the loss is more than 5 QALYs; 
severe (grade II) if the loss is between 1 and 5 QA-
LYs; and not severe (grade III) if the loss is less than 
1 QALY (for further discussion of this framework 
and its application, see Norheim and Gloppen).31 
Ideally, these thresholds should be discussed and 
determined in health-policy deliberations, but in 
the absence of agreement on thresholds, we believe 
that these are not unreasonable. In addition, we 
assessed whether effectiveness and cost-effective-
ness had been documented in high-quality studies 
(preferably from randomized controlled trials). For 
the detailed framework, see Table 1.
Results
In our material of 37 randomly selected cases which 
concerned access to medicines and were brought to 
the Constitutional Chamber of the Supreme Court, 
we found that 2.7% fell into priority group 1 (highest 
Criterion Information needed Measure* Grading
Effectiveness Mortality 
Morbidity
QALY gain** I  > 1 QALY 
II < 1 & > 0.5 QALY 
III < 0.5 QALY
Severity of disease Mortality 
Morbidity
QALY loss*** I > 5 QALY loss 
II > 1 QALY loss < 5 QALY loss 
III < 1 QALY loss
Cost-effectiveness Total and incremental 
cost effectiveness
Cost per QALY gained I Cost-effective: < GDP per capita 
II Intermediate: > GDP per capita < 3 x GDP per capita 
III Not cost-effective: > 3 x GDP per capita
Quality of evidence Type of studies doc-
umenting treatment 
effects
Evidence grading 
systems****
I Meta-analysis or randomized clinical trial 
II Observational, non-comparative studies 
III Single case reports
Table 1  Criteria for priority classification
* = Quality-Adjusted Life Years = QALYs 
** = Compared to standard intervention 
*** = Compared to normal healthy life expectancy 
**** = Such as the AGREE instrument or others
priority), 27% in group II, 48.6% in group III, and 
21.6% in group IV (see Table 2). Only three of the 
drugs are already on the official WHO essential 
drugs list.
 Table 2 provides more detail and summarizes all 
evidence for each criterion and combines it into an 
overall assessment of each medicine. Each medicine 
is classified into one of four priority groups with de-
clining rank. In order to qualify for priority group I, 
the condition and medication in question must be 
evaluated as grade I for each criterion. The kind of 
conditions and number of cases are also listed.
 A summary of priority-relevant evidence is 
listed in Table 3. Although there is uncertainty 
concerning evidence for effectiveness, severity, 
and cost-effectiveness for many cases, the evidence 
available from studies and HTA reports enabled us 
to evaluate each medicine according to predefined 
criteria for priority classification. For comparison, 
we have also included an evaluation of ARV therapy 
for HIV/AIDS that was introduced in 1997 in Costa 
Rica. Only one of the successful medications from 
2008 is as effective or addresses such a severe condi-
tion as antiretroviral therapy for HIV/AIDS. Table 
4 shows evaluation and grading of each medication 
according to the predefined priority criteria. We see 
from Tables 3 and 4 that some medications provide 
a QALY gain (effectiveness) of less than 1 QALY 
(grade II and III), while several have higher gains in 
terms of quality-adjusted life years.
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Medicine Condition Cases I II III IV
Bevacizumab Colon cancer 3 3
Carvedilol Heart disease 1 1
Cyclofosfamid Breast cancer 1 1
Erlotinib Lung cancer 1 1
Imatinib (Glivec) Leukemia 2 2
Lactulosa Portosystemic encephalopathy 1 1
Escitalopram (Lexapro/Cipralex) Depression 1 1
Medication for dialysis (serum) Kidney insufficiency 1 1
Nilotinib (Tasigna) Leukemia 1 1
Octreotidelar Pituitary adenoma 1 1
Omeprazol Stomach ailments 1 1
Pamidronato de sodio Osteogenesis imperfecta 1 1
Clopidogrel (Plavix) Heart disease 2 2
Clopidogrel (Plavix) Cerebral insult 2 2
Potassium gloconate Hypothyroidism 1 1
Risperdal Autism 1 1
Risperidona Vascular dementia 1 1
Alendronate Osteoporosis 2 2
Rituximab Lymphoma Hodgkin’s desease 1 1
Sunitinib Kidney cancer with metastasis 2 2
Ralidomid Spinal cord cancer 1 1
Trastuzumab Breast cancer 6 6
Zometa Breast cancer with bone metastasis 1 1
Sildenafil (Viagra) Pulmonary hypertension 1 1
Capecitabine (Xeloda) Bilateral lung metastasis 1 1
Sum (%)     1 (2.7) 10 (27.0) 18 (48.6) 8 (21.6)
Table 2  Priority classification of cases
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Medication Condition Effectiveness (indi-
vidual QALY gain)
Severity of 
disease (QALY 
loss)
Cost 
($) per 
QALY
Quality of evi-
dence
References
Bevacizumab Colon cancer 0.85 18 51,120 2 RCT# 69
Carvedilol Heart disease 2,309 RCT 70
Ciclofosfamida Breast cancer
Erlotinib Lung cancer
Imatinib (Glivec) Leukemia 1.00 >10 74,315 4 RCT 7172
Lactulose Portosystemic 
encephalop-
athy
1.4 28.4 57,000 Decision model + 
metanalysis of 10 
RCT (low quality, 
weak evidence)
73
Escitalopram 
(Lexapro/Cipr-
alex)
Depression 3 >5 28,167 74
Medication for 
dialysis
Kidney insuf-
ficiency
10 20 100,000 Standardly used 
in high-income 
countries
75
Nilotinib (Ta-
signa)
Leukemia Not found Not found Not 
found
Experimental. 
Rejected by NICE 
UK 2009
76
Octreotidelar Pituitary 
adenoma
Not found Not found Not 
found
Experimental? No HTA§/CEA 
study found
Omeprazol Stomach ail-
ments/hiatus 
hernia
1 2 3.000 Standardly used 
in high-income 
countries
No HTA/CEA 
study found
Pamidronatode 
sodio
Osteogenesis 
imperfecta
Not found Not found Not 
found
Experimental? 
Approved by Atnea 
(US)
No HTA/CEA 
study found
Clopidogrel 
(Plavix)
Heart disease 0.1 9.19 15.400 RCT + CEA$ 77
Clopidogrel (Pla-
vix)Carvedilol 
(Coreg)
Cerebral 
insult
Search RCT 7870
Potassium glo-
conate
Hypothyroid-
ism
Not found Not found Not 
found
- No HTA/CEA 
study found
Risperdal Autism Not found Not found Not 
found
Experimental. Not 
approved in 2005 
by US Food and 
Drug Administra-
tion (FDA)
No HTA/CEA 
study found
Risperidona Vascular 
dementia
NE NE Not 
found
No HTA/CEA 
study found
Alendronate Osteoporosis 0.15 2 11,600 RCT 79
Rituximab Lymphoma 
Hodgkin’s 
disease
0.82 >5 17,271 1 RCT 80
Sunitinib Kidney cancer 
with metas-
tasis
0.20 19,5 74,000 1 RCT + CEA 81
Talidomida Spinal cord 
cancer
Not found Not found Not 
found
Experimental? No HTA/CEA 
study found
Trastuzumab Breast cancer 1.54 10,45 18,970 RCT + CEA 82
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Medical 
treatment with 
zometa
Breast cancer 
with bone 
metastasis
Sildenafil 
(Viagra)
Pulmonary 
hypertension
0.2 >5 Not 
found
Only one small 
open label trial of 
Sildenafil 50 mg 
orally
83
Capecitabine 
(Xeloda)
Bilateral lung 
metastasis
0.2 >5 Uncertain 1 RCT for com-
bination therapy, 
weak evidence
84
Comparison case: 
Antiretroviral 
therapy
HIV eligible 
for treatment
> 3.5 > 20 1180 * RCT + CEA 85
Table 3  (continued) Evidence for grading and priority classification
* = cost in recent analysis, not at the point of introduction (1997)
# RCT = Randomized clinical trial 
§ HTA Health technology assessment 
$ CEA = Cost-effectiveness analysis
Medication Condition Number 
of cases
WHO 
Essential 
drug list
Effec-
tive
ness
Sever-
ity
Cost-
effect
iveness
Strength 
of evi-
dence
Priority 
group
Bevacizumab Colon cancer 3 0 II I III II III
Carvedilol Heart disease 1 0     I I I
Ciclofosfamida Breast cancer 1 0       II
Erlotinib Lung cancer 1 0       III
Imatinib (Glivec) Leukemia 2 0 I I III I III
Lactulosa Portosystemic en-
cephalopathy
1 0 I I III III III
Escitalopram 
(Lexapro/Cipralex)
Depression 1 0 I I II II II
Medication for dial-
ysis (serum)
Kidney insufficiency 1 0 I I III I III
Nilotinib (Tasigna) Leukemia 1 0 NE* NE NE Experi-
mental
IV
Octreotidelar Pituitary adenoma 1 0 NE NE NE Experi-
mental
IV
Omeprazol Stomach ailments 1 YES I II I I II
Pamidronato de 
sodio
Osteogenesis imper-
fecta
1 0 NE NE NE Experi-
mental
IV
Clopidogrel (Plavix) Heart disease 2 0 III I II I III
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Clopidogrel (Plavix) Cerebral insult 2 0       III
Potassium gloconate Hypothyroidism 1 0 NE NE NE Experi-
mental
IV
Risperdal Autism 1 0 NE NE NE Experi-
mental
IV
Risperidona Vascular dementia 1 0 NE NE NE Experi-
mental
IV
Medication alendro-
nato sodico
Osteoporosis 2 0 III II II I III
Rituximab Lymphoma Hodgkin’s 
desease
1 0 II I II II II
Sunitinib Kidney cancer with 
metastasis
2 0 III I III II III
Talidomida Spinal cord cancer 1 0 NE NE NE Experi-
mental
IV
Trastuzumab Breast cancer 6 0 I I II I II
Table 4  Evaluation and grading of each medication 
according to the priority criteria
* NE = no evidence
Most conditions, however, are severe. We see from 
Table 3 that many conditions imply a QALY loss of 
five or more. Some groups can expect 1-5 QALYs 
lost, while there are no non-severe cases with con-
ditions in category III, that is, with expected losses 
of less than 1 QALY.
 In terms of cost-effectiveness, few interventions 
are evaluated as highly cost-effective; many are eval-
uated as not cost-effective; some as intermediate; 
and for 10 cases, there were no cost-effectiveness 
analyses available.
 Eight of the medications are evaluated as exper-
imental, according to evidence by an HTA agency 
deemed trustworthy as of 2008; all the others are 
proven effective in large randomized clinical trials. 
Discussion
In this study, we review 37 cases from Costa Rica 
concerning access to medicines brought to the 
court and won in 2008. After considering available 
evidence, we classified them according to standard 
fairness criteria from the public health and priority 
setting literature. Of the 37 cases evaluated, 73% can 
be classified as either low priority or experimental. 
These medications can be described as providing 
‘marginal’ health benefits for very severe conditions 
at a high cost for the health care system. For the re-
maining 27% of the cases falling into priority class I 
or II, it is not unreasonable—according to our eval-
uation—that those were successful. Trastuzumab 
(herceptin) for breast cancer is the largest group in 
this category.
 How robust is our system for priority classifica-
tion? There is some agreement on priority criteria, 
but reasonable people may disagree on classification. 
Every system of priority classification is bound to be 
controversial. Our method is based on all available 
evidence, and we use explicit criteria grounded in 
theories of fair priority setting in health.
 Priority setting according to cost-effectiveness 
is particularly controversial. WHO and others 
have suggested that interventions be classified as 
highly cost-effective if cost per QALY is less than 
one GDP per capita; intermediate if cost per QALY 
is more than 1 x GDP per capita and less than 3 x 
GDP per capita; and not cost-effective if cost per 
QALY is above 3 x GDP per capita.32 For example, 
if treatment for advanced breast cancer would cost 
l   (con i ue )  Evaluation and grading of each medication according to the priority criteria
* NE = o evidence
O. F. Norheim and B. M. Wilson/Health and Human Rights 16/2 (2014) 
D E C E M B E R  2 0 1 4    N U M B E R  2    V O L U M E  1 6   Health and Human Rights Journal 58 
less than $10,800 per QALY gained, it would be 
considered highly cost-effective. According to this 
rule of thumb, all interventions costing more than 
approximately $32,400 per QALY gained would be 
judged as not cost-effective. The underlying ethical 
rationale for considering cost-effectiveness is that 
there may be unmet needs in the system for which 
there exist more cost-effective interventions, and 
that population health is more efficiently improved 
if priority is given to the most cost-effective inter-
ventions first.
 Moreover, our framework requires that all crite-
ria be satisfied cumulatively, that is, each condition 
must be severe enough, and the treatment effective 
and cost-effective enough to qualify for a priority 
group. An alternative would be to balance the cri-
teria against each other so that, for example, since 
HER2+ breast cancer is very severe (grade I) and 
the treatment (Trastuzumab) effective (grade I) in 
terms of effectiveness but only grade II in cost-ef-
fectiveness, a judgment could be made to adjust 
the cost-effectiveness threshold so that overall the 
case is classified as priority group I. This accords 
with commonly held notions of fair distribution of 
health benefits.  However, there is no agreement on 
how much the cost-effectiveness threshold should 
be adjusted when the intervention targets a very se-
vere condition where the QALY loss is particularly 
great.33 We therefore used the cumulative grading 
system instead of a weighted grading system.
 It is important to note that this method does not 
capture all aspects relevant for evaluation of equity. 
Classification in priority groups is only one part 
of the evaluation. The method focuses on fair and 
efficient distribution of health outcomes, but is not 
assessing fair access to medicines in terms of the so-
cioeconomic status of patients or other issues related 
to non-discrimination. For an overall assessment, 
we also need to know more about whether there 
are many other unmet medical needs that would 
have fallen into priority group I or II. It is worth 
noting that invariably, all cases concerned claim-
ants with high severity of disease that would have 
a large impact on health inequality if not treated. 
This fact is probably given high weight in the court’s 
deliberation on individual cases. One may question 
whether our classification has assigned enough 
weight to this criterion. This issue can be seen as an 
aspect of the familiar trade-off between efficiency 
and equity.34 Moreover, we evaluate the conditions 
and medicines for the typical patient, and are aware 
that particular characteristics of individual patients 
may vary.
 By taking a random sample of cases from our 
database, we attempted to create a representative set 
of medical cases. We know from follow-up studies 
conducted by the Sala IV that the CCSS’s compliance 
with the court’s decisions is almost universal, and 
patients regularly receive the medications claimed 
in successful health rights cases.35 However, while 
the original database is the most comprehensive 
representation of all health rights cases filed and 
decided by the court, it is possible that some cas-
es have been overlooked due to the difficulties of 
searching through the 18,000 cases filed in 2008. 
Adding to the difficulties understanding the success 
or failure of medication claims is the court’s ten-
dency to combine similar individual cases together 
with a single decision number. Our sample, even if 
randomly selected, is quite small.
 More importantly, as Figures 2 and 3 show, 
our database of cases concerning medicine is not 
representative of all health rights cases brought to 
the court. We have not assessed cases concerning 
non-discrimination, waiting lists, quality of care, 
infrastructure, or surgery. Nor have we examined 
the cases in which the court’s decision was followed 
by the CCSS’s inclusion of the claimed medication 
into the official medications list, as happened with 
the AIDS medications in 1997, and more recently, 
the multiple sclerosis cases.36 Finally, we have not 
examined the recent health rights decisions decided 
in favor of entire classes of people. Further analysis 
of a larger and more comprehensive sample, using 
the same methods, is clearly warranted.
 A 2009 decision ruled that everyone aged over 65 
years should be granted access to vaccinations for 
pneumococcus, which was previously provided only 
to children under 2 years (a high-risk category).37 A 
group of senior citizens filed the case, arguing that 
they, too, were a high-risk group for pneumococcal 
infection, and that the CCSS was denying their right 
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to health. Their claim was successful, and the CCSS 
was forced to vaccinate them (and all other people 
over 65) against pneumococcus and rotavirus at a 
total cost of $8 million per year.38 This confirmed 
the fears of the health rights litigation critics that 
the Sala IV’s decisions were diverting scarce re-
sources from the higher priorities set by the CCSS’s 
experts. In the pneumococcus case, though, the 
Sala IV invited the Minister of Health to present her 
medical experts’ views to the court before it made 
its decision. According to one senior letrado, this 
evidence “probably tilted the case in favor of the se-
niors’ demand to have access to the vaccine.”39 That 
is, the actions of the court were more dialogic than 
previous decisions and were more of a class settle-
ment than the previous inter partes health rights 
decisions (i.e. binding only on the parties involved 
in the case).40
Conclusion
Does health rights litigation that seeks access to 
medications not covered by an official medications 
list lead to more fairness in access to medicines and 
distribution of health benefits? For the case of Costa 
Rica, we have shown that of the 37 cases evaluated, 
about 70% could be classified as either low priority 
or experimental and can be described as providing 
‘marginal’ health benefits for very severe conditions 
at a high cost to the health care system. For the re-
maining 30% of the cases falling into priority class 
I or II, it is not unreasonable—according to our 
evaluation—that these were successful.
 The priority classification system applied here 
makes it possible to distinguish medications that 
could be assigned high, medium, low or no prior-
ity, according to available evidence and relatively 
standard fairness criteria from the public health 
and priority-setting literature. Further studies of a 
representative set of cases are needed to evaluate 
whether health litigation contributes to a more or 
less fair distribution of health in Costa Rica. Like 
the current analysis, it could be based on a frame-
work specifying widely agreed principles of fair 
distribution, and assigning high priority to health 
services that have a large impact on life expectancy 
(improves average health), and targeting those with 
least lifetime health measured in terms of quality 
of life and premature mortality (reducing overall 
health inequality). If a majority of the successful 
litigated medication cases results in access to new 
expensive medications with only marginal benefits, 
we cannot conclude that litigation led to more fair-
ness in access to medications in Costa Rica. More 
than 70% of the successful cases analyzed concerned 
medications judged to be of low priority.
 While consistently pushing back against crit-
icism that it is making poorly informed medical 
decisions and placing an untenable financial burden 
on the CCSS, the court actively sought partners and 
input to create a process that would allow the mag-
istrates to make more informed decisions on health 
rights cases. The court recently signed a Technical 
Cooperation Plan (Plan de cooperación técnica) 
with the Cochrane Collaboration that involved 
all major stakeholders in the health care system. 
This new collaboration, signed in May 2014, will 
facilitate an ongoing dialogue between interested 
health specialists on important questions of “equi-
ty, efficiency, design and implementation of public 
policies concerned with prioritization, law, and the 
judicialization of health.”41 It will also provide the 
Sala IV with access to the Cochrane Collaboration’s 
extensive medical databases and provide training to 
relevant court personnel to better understand spe-
cialized medical information.42 As a consequence of 
the collaboration, the Sala IV should be able to make 
better-informed health rights decisions that benefit 
from previously unavailable technical medical in-
formation and input from relevant stakeholders.
 To include all stakeholders in mechanisms for 
systematic and impartial consideration of the 
medical evidence, the costs, and the distributional 
impact of introducing new medications is an im-
portant first step toward making the priority-setting 
process fairer.
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